Literature DB >> 19584816

Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons.

Ayse Ulusoy1, Gurdal Sahin, Tomas Björklund, Patrick Aebischer, Deniz Kirik.   

Abstract

Short-hairpin RNA (shRNA)-mediated gene knockdown is a powerful tool for targeted gene silencing and an emerging novel therapeutic strategy. Recent publications, however, reported unexpected toxicity after utilizing viral-mediated shRNA knockdown in vivo. Thus, it is currently unclear whether shRNA-mediated knockdown strategy can be used as a safe and efficient tool for gene silencing. In this study, we have generated rAAV vectors expressing shRNAs targeting the rat tyrosine hydroxylase (TH) mRNA (shTH) for testing the efficacy of in vivo TH knockdown in the nigral dopaminergic neurons. At high titers, not only the shTH vectors but also the scrambled and green fluorescence protein (GFP)-only controls caused cell death. In a dose-response study, we identified a dose window leading to >60% decrease in TH(+) neurons without any change in vesicular monoamine transporter-2 (VMAT2) expression. Moreover, using the safe and efficient dose, we showed that dopamine (DA) synthesis rate was significantly reduced and this lead to emergence of motor deficits in the shTH-expressing rats. Interestingly, these animals showed very robust and long-lasting recovery after a single systemic L-3,4-dihydroxyphenylalanine (L-DOPA) administration beyond what can be achieved in 6-hydroxydopamine (6-OHDA)-lesioned rats. Our results have implications for both mechanistic and therapeutic studies utilizing long-term shRNA-mediated gene silencing in the nigrostriatal projection system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584816      PMCID: PMC2835264          DOI: 10.1038/mt.2009.142

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  28 in total

1.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.

Authors:  Dirk Grimm; Konrad L Streetz; Catherine L Jopling; Theresa A Storm; Kusum Pandey; Corrine R Davis; Patricia Marion; Felix Salazar; Mark A Kay
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

2.  Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.

Authors:  Edgardo Rodriguez-Lebron; Eileen M Denovan-Wright; Kevin Nash; Alfred S Lewin; Ronald J Mandel
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

3.  Leptin receptor signaling in midbrain dopamine neurons regulates feeding.

Authors:  Jonathan D Hommel; Richard Trinko; Robert M Sears; Dan Georgescu; Zong-Wu Liu; Xiao-Bing Gao; Jeremy J Thurmon; Michela Marinelli; Ralph J DiLeone
Journal:  Neuron       Date:  2006-09-21       Impact factor: 17.173

4.  Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.

Authors:  D Kirik; C Rosenblad; A Bjorklund; R J Mandel
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

5.  Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome.

Authors:  Sergei Musatov; Walter Chen; Donald W Pfaff; Charles V Mobbs; Xue-Jun Yang; Deborah J Clegg; Michael G Kaplitt; Sonoko Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-06       Impact factor: 11.205

6.  Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo.

Authors:  Eileen M Denovan-Wright; Edgardo Rodriguez-Lebron; Alfred S Lewin; Ronald J Mandel
Journal:  Neurobiol Dis       Date:  2007-11-12       Impact factor: 5.996

7.  Adeno-associated virus-mediated knockdown of melanocortin-4 receptor in the paraventricular nucleus of the hypothalamus promotes high-fat diet-induced hyperphagia and obesity.

Authors:  Jacob C Garza; Chung Sub Kim; Jing Liu; Wei Zhang; Xin-Yun Lu
Journal:  J Endocrinol       Date:  2008-06       Impact factor: 4.286

8.  Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.

Authors:  Jodi L McBride; Ryan L Boudreau; Scott Q Harper; Patrick D Staber; Alex Mas Monteys; Inâs Martins; Brian L Gilmore; Haim Burstein; Richard W Peluso; Barry Polisky; Barrie J Carter; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-08       Impact factor: 11.205

9.  An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections.

Authors:  Eduardo M Torres; Alicia Meldrum; Deniz Kirik; Stephen B Dunnett
Journal:  J Neurosci Methods       Date:  2006-06-23       Impact factor: 2.390

10.  Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease.

Authors:  Sandro Alves; Isabel Nascimento-Ferreira; Gwennaëlle Auregan; Raymonde Hassig; Noëlle Dufour; Emmanuel Brouillet; Maria C Pedroso de Lima; Philippe Hantraye; Luís Pereira de Almeida; Nicole Déglon
Journal:  PLoS One       Date:  2008-10-08       Impact factor: 3.240

View more
  34 in total

Review 1.  Lentiviral vector-mediated RNA silencing in the central nervous system.

Authors:  Thomas H Hutson; Edmund Foster; Lawrence D F Moon; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther Methods       Date:  2013-11-01       Impact factor: 2.396

Review 2.  AAV: An Overview of Unanswered Questions.

Authors:  Kenneth I Berns; Nicholas Muzyczka
Journal:  Hum Gene Ther       Date:  2017-04       Impact factor: 5.695

3.  Viral delivery of shRNA to amygdala neurons leads to neurotoxicity and deficits in Pavlovian fear conditioning.

Authors:  Christopher A de Solis; Roopashri Holehonnur; Anwesha Banerjee; Jonathan A Luong; Srihari K Lella; Anthony Ho; Bahram Pahlavan; Jonathan E Ploski
Journal:  Neurobiol Learn Mem       Date:  2015-07-13       Impact factor: 2.877

4.  Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.

Authors:  Joanna A Korecka; Elizabeth B Moloney; Ruben Eggers; Barbara Hobo; Sanny Scheffer; Nienke Ras-Verloop; R Jeroen Pasterkamp; Dick F Swaab; August B Smit; Ronald E van Kesteren; Koen Bossers; Joost Verhaagen
Journal:  J Neurosci       Date:  2017-08-21       Impact factor: 6.167

Review 5.  Recombinant AAV as a platform for translating the therapeutic potential of RNA interference.

Authors:  Florie Borel; Mark A Kay; Christian Mueller
Journal:  Mol Ther       Date:  2013-12-19       Impact factor: 11.454

6.  Adeno-Associated Virus Vector Mobilization, Risk Versus Reality.

Authors:  Liujiang Song; R Jude Samulski; Matthew L Hirsch
Journal:  Hum Gene Ther       Date:  2020-10       Impact factor: 5.695

7.  The Lipase Activity of Phospholipase D2 is Responsible for Nigral Neurodegeneration in a Rat Model of Parkinson's Disease.

Authors:  Hector R Mendez-Gomez; Jasbir Singh; Craig Meyers; Weijun Chen; Oleg S Gorbatyuk; Nicholas Muzyczka
Journal:  Neuroscience       Date:  2018-03-09       Impact factor: 3.590

8.  Knockdown of tyrosine hydroxylase in the nucleus of the solitary tract reduces elevated blood pressure during chronic intermittent hypoxia.

Authors:  Chandra Sekhar Bathina; Anuradha Rajulapati; Michelle Franzke; Kenta Yamamoto; J Thomas Cunningham; Steve Mifflin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-18       Impact factor: 3.619

9.  Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.

Authors:  Christina E Khodr; Amanda Becerra; Ye Han; Martha C Bohn
Journal:  Brain Res       Date:  2014-01-21       Impact factor: 3.252

10.  Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system.

Authors:  Erich M Ehlert; Ruben Eggers; Simone P Niclou; Joost Verhaagen
Journal:  BMC Neurosci       Date:  2010-02-18       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.